ABL partners with KaliVir Immunotherapeutics to advance development of oncolytic viruses
Nosopharm welcomes new members to supervisory board
Thabor Therapeutics secures €2 million in deep tech financing from Bpifrance
Naobios delivers FluGen Inc’s M2SR influenza vaccine candidate for upcoming clinical trials
BIOTEM implements new industrial unit dedicated to development and production of immunoassays
BioWin, CETIC and essenscia wallonie launch BioMan initiative to accelerate digitization of bioprocesses in Wallonia
Nosopharm and GNA Now announce positive results for the late preclinical development of the first-in-class antibiotic NOSO-502
Thabor Therapeutics appoints Jérémie Mariau as CEO
